Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445432 | 0.83 | HSD17B10 (0.41) | APPHSD17B10TSHRP2RX1HPGD | |
| SCHEMBL6441902 | 0.83 | MAPT (0.46) | APPHSD17B10TSHRP2RX1HPGD | |
| SCHEMBL3137556 | 0.79 | TSHR (0.42) | APPHSD17B10TSHRP2RX1HPGD | |
| SCHEMBL7931554 | 0.79 | EPAS1 (0.42) | CNR2KCNH2IDO1 | |
| SCHEMBL8778326 | 0.79 | MAOB (0.54) | APPHSD17B10P2RX1ALOX15ALDH1A1 | |
| SCHEMBL2097133 | 0.78 | APP (0.49) | APPP2RX1KCNH2TMEM97SIGMAR1 | |
| SCHEMBL14121378 | 0.78 | APP (0.49) | APPP2RX1KCNH2TMEM97SIGMAR1 | |
| SCHEMBL4849499 | 0.78 | APP (0.49) | APPHSD17B10TSHRHPGDALOX15 | |
| SCHEMBL13319145 | 0.76 | EPAS1 (0.44) | TSHRSMN1; SMN2CNR2KCNH2CYP3A4 | |
| SCHEMBL213780 | 0.76 | MAOA (0.49) | APPHPGDALOX15ALOX12SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-8604065-B2 | Pyridyl cyanoguanidine derivatives | Zhang, Hesheng (CN) | 2013-12-10 | — | — | US | disclosed |
| EP-2593427-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
| US-20120309797-A1 | PYRIDYL CYANOGUANIDINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-12-06 | — | — | US | disclosed |
| WO-2012007883-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007883-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| CN-1738794-B | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY | 2010-12-22 | — | — | CN | disclosed |
| CN-1738794-A | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY (US) | 2006-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | APP 2523/4885HSD17B10 2861/4885TSHR 2473/4885 |
| US-20120309797-A1 | PYRIDYL CYANOGUANIDINE DERIVATIVES | PNPO, XDH, PDXK | APP 4105/4885HSD17B10 3965/4885TSHR 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.